Reducing Fibrinogen and Factor XIII Using Double-Filtration Plasmapheresis for Antibody-Mediated Rejection: Predictive Models

2018 ◽  
Vol 46 (3) ◽  
pp. 239-245 ◽  
Author(s):  
Thomas Jouve ◽  
Raphaël Marlu ◽  
Paolo Malvezzi ◽  
Landry Seyve ◽  
Jocelyne Maurizi ◽  
...  
Keyword(s):  
Factor Xiii ◽  
Prospective Trial ◽  
Human Leukocyte ◽  
Kidney Transplant Recipients ◽  
Clotting Factors ◽  
Leukocyte Antigen ◽  
Antibody Mediated Rejection ◽  
Double Filtration Plasmapheresis ◽  
Before And After ◽  
Double Filtration

Background/Aims: Antibody-mediated rejection (AMR) is related to circulating donor-specific anti-human leukocyte antigen alloantibodies (DSAs). DSAs can be removed by apheresis, for example, double-filtration plasmapheresis (DFPP). However, DFPP removes some clotting factors (fibrinogen and factor XIII [FXIII]). Methods: This was a prospective trial including 6 DSA-mediated AMR kidney transplant recipients. Patients received 2 cycles of 3–4 consecutive DFPP sessions followed by 1 injection of rituximab (break of 4–5 days between the 2 cycles). We monitored fibrinogen and FXIII levels before and after each session of DFPP. Results: Overall, fibrinogen and FXIII levels were significantly decreased after each session, and were significantly reduced between the very first and very last sessions. In addition, we established a model that predicted fibrinogen and FXIII values after each session and after 2 cycles. Conclusion: We established a model in order to predict fibrinogen and FXIII depletion after DFPP sessions; it may help clinicians supplement fibrinogen and/or FXIII when appropriate.

How to improve clotting factors depletion in double‐filtration plasmapheresis

2021 ◽  
Author(s):  
Hamza Naciri Bennani ◽  
Raphael Marlu ◽  
Florian Terrec ◽  
Lionel Motte ◽  
Landry Seyve ◽  
...  
Keyword(s):  
Clotting Factors ◽  
Double Filtration Plasmapheresis ◽  
Double Filtration

Kidney Transplantation 1: An Overview--Recipient Evaluation and Immunosuppression

2017 ◽  
Author(s):  
Belinda T. Lee ◽  
Anil Chandraker ◽  
Jamil Azzi ◽  
Martina M McGrath
Keyword(s):  
Kidney Transplantation ◽  
Human Leukocyte ◽  
Basic Knowledge ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Early Management ◽  
Leukocyte Antigen ◽  
Medical Evaluation ◽  
Stage Renal Disease ◽  
End Stage

Kidney transplantation remains the optimal renal replacement therapy for patients with end-stage renal disease (ESRD). A timely referral to kidney transplantation and a thorough pretransplantation evaluation ensure improvement in the morbidity and mortality of ESRD patients. Basic knowledge of immune biology and an in-depth understanding of the different induction and maintenance therapies used post kidney transplantation are imperative for optimal patient management. In this review, we discuss the multidisciplinary process of pretransplantation evaluation of kidney transplant recipients. We also discuss state-of–the-art early management post kidney transplantation with the different immunosuppressive therapies currently available. This review contains 3 figures, 11 tables, and 106 references. Key words: crossmatch, donor-specific antibody, immunosuppression, human leukocyte antigen, immunosuppression, induction, maintenance, medical evaluation, transplantation

Plasmapheresis Therapy in Kidney Transplant Rejection

2018 ◽  
Vol 47 (1-3) ◽  
pp. 73-84 ◽  
Author(s):  
Pan Xie ◽  
Min Tao ◽  
Kanfu Peng ◽  
Hongwen Zhao ◽  
Keqin Zhang ◽  
...  
Keyword(s):  
End Stage Renal Disease ◽  
Multimodal Treatment ◽  
Transplant Rejection ◽  
Human Leukocyte ◽  
Economic Costs ◽  
Leukocyte Antigen ◽  
Antibody Mediated Rejection ◽  
Stage Renal Disease ◽  
End Stage ◽  
Optimal Treatment Strategy

Kidney transplantation (KT) is considered an optimal treatment strategy for end-stage renal disease. But human leukocyte antigen-sensitized, ABO-incompatible and antibody-mediated rejection might be the alarming hurdles in KT. Therapeutic plasma exchange is the mainstay of the antibody reduction therapy for reducing autoantibody more effectively. Even in the treatment for highly sensitized patients, it has played an indispensable role. However, clinicians should tailor therapies to individual patient’s needs and multimodal treatment will bring better outcomes. Early diagnosis and precise treatment would reduce morbidity, mortality, and economic costs.

Double Filtration Plasmapheresis Can Decrease Factor XIII Activity

2007 ◽  
Vol 11 (3) ◽  
pp. 165-170 ◽  
Author(s):  
Norio Hanafusa ◽  
Yasushi Kondo ◽  
Makoto Suzuki ◽  
Akihide Nakao ◽  
Eisei Noiri ◽  
...  
Keyword(s):  
Factor Xiii ◽  
Double Filtration Plasmapheresis ◽  
Double Filtration
Sign in / Sign up

Export Citation Format

Share Document